Pfizer Discontinues Danuglipron Trials Due to High Dropout Rates The company decided to continue forward with its twice-a-day formulation of danuglipron
At 10 mg/mL, 40 units delivers 4.0 mg, which exceeds the maximum approved dose and would be considered dangerous without specific medical guidance
WHO IT'S FOR Anyone using or planning to start a GLP-1 medication semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or liraglutide (Saxenda, Victoza)
Categories Pharmaceutical + - Analgesic & Muscle-Relaxant Anti-Allergy & Anti-Tussive Anti-Anemic Anti-Chelating Anti-infective Anti-Neoplastic Anti-Thrombotic Cardiovascular Endocrinology & Metabolism Gastrointestinal Gynecology, Urology & Sex Hormones Hepatology Hospital Solutions Neurology & Psychiatry Orthopedics & Rheumatology Respiratory Systemic-Hormones Biopharmaceutical Nutraceutical + - HERBAL SUPPLEMENTS PROBIOTICS & ENZYMES VITAMINS & MINERALS Nutrition + - Baby Cereals Clinical Nutrition Mead Johnsons Division Nurtumil Division Nurture Intelligence Division Consumer Medical Devices & Disposables + - BLOOD TRANFUSION CRITICAL CARE & ANAESTHESIA IV ADMINSTRATION OPHTHALMOLOGY OTHERS RENAL CARE SURGICALS GLOVES Semavi Generic: Semaglutide Form: Tablet Strength: 3mg, 7mg & 14mg Presentation: 10s Indication: Semavi Tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Semavi SmPC
Compounded GLP-1s are not FDA-approved finished drug products
